

Bertrand Tombal

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2439253/bertrand-tombal-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers

11,769
citations

54
h-index

106
g-index

212
ext. papers

14,366
ext. citations

7.7
avg, IF

5.94
L-index

#	Paper	IF	Citations
185	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022 , 18, 35-45	3.6	0
184	Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	30
183	Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial. <i>BJU International</i> , 2021 ,	5.6	1
182	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 1287-1297	2.8	1
181	Case Report: Early Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases.. <i>Frontiers in Oncology</i> , 2021 , 11, 782166	5.3	1
180	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 680-688	6.2	9
179	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , 2020 , 10, 246	5.3	5
178	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
177	Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. <i>European Urology</i> , 2020 , 78, 603-614	10.2	7
176	Shortening the acquisition time of whole-body MRI: 3D T1 gradient echo Dixon vs fast spin echo for metastatic screening in prostate cancer. <i>European Radiology</i> , 2020 , 30, 3083-3093	8	10
175	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 284-294	3.3	37
174	Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. <i>Lancet Oncology, The</i> , 2020 , 21, e18-e28	21.7	232
173	Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. <i>European Journal of Cancer</i> , 2020 , 125, 142-152	7.5	4
172	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 217-225	13.4	10
171	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , 2020 , 77, 223-250	10.2	60
170	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology, The</i> , 2020 , 21, 1513-1525	21.7	13
169	Whole-body magnetic resonance imaging for prostate cancer assessment: Current status and future directions. <i>Journal of Magnetic Resonance Imaging</i> , 2020 ,	5.6	6

168	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2506-2518	59.2	219
167	Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment. <i>World Journal of Urology</i> , 2019 , 37, 2585-2595	4	5
166	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 556-569	21.7	56
165	Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 24-38	6.2	108
164	Managing Nonmetastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019 , 75, 285-293	10.2	83
163	The changing role of radium-223 in metastatic castrate-resistant prostate cancer: has the EMA missed the mark with revising the label?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 63, 170-182	1.4	2
162	Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. <i>European Urology</i> , 2019 , 76, 115-124	10.2	90
161	Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. <i>European Urology Oncology</i> , 2019 , 2, 456-463	6.7	8
160	Androgen receptor-targeted agents in the management of advanced prostate cancer. <i>Lancet Oncology</i> , 2019 , 20, 1628-1630	21.7	0
159	Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences. <i>European Radiology</i> , 2019 , 29, 4503-4513	8	28
158	Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 164-170	13.4	180
157	Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer. <i>BJU International</i> , 2019 , 123, 411-420	5.6	13
156	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 694-701	13.4	32
155	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. <i>European Urology Focus</i> , 2018 , 4, 369-375	5.1	8
154	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211	10.2	313
153	Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. <i>Journal of Urology</i> , 2018 , 199, 459-464	2.5	11
152	Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 332-340	3.3	44
151	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , 2018 , 19, e696-e708	21.7	59

150	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. <i>Lancet Oncology, The</i> , 2018 , 19, e534-e545	21.7	65
149	Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins. <i>Scandinavian Journal of Urology</i> , 2017 , 51, 20-26	1.6	12
148	Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. <i>Journal of Urology</i> , 2017 , 198, 1054-1060	2.5	10
147	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 610-617.e3	3.3	18
146	The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. <i>European Journal of Cancer</i> , 2017 , 87, 21-29	7.5	20
145	Intraparenchymal Renal Artery Pseudoaneurysm and Arteriovenous Fistula on a Solitary Kidney Occurring 38 Years after Blunt Trauma. <i>Case Reports in Urology</i> , 2017 , 2017, 3017501	0.5	5
144	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. <i>European Urology</i> , 2017 , 71, 151-154	10.2	202
143	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. <i>European Urology</i> , 2017 , 71, 886-893	10.2	61
142	Rationale for Modernising Imaging in Advanced Prostate Cancer. <i>European Urology Focus</i> , 2017 , 3, 223-239	3.9	46
141	Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. <i>European Journal of Cancer</i> , 2016 , 69, 9-18	7.5	14
140	Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease. <i>Prostate</i> , 2016 , 76, 1024-33	4.2	34
139	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 70, 675-683	10.2	57
138	Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND). <i>European Urology</i> , 2016 , 69, 720-727	10.2	31
137	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology</i> , 2016 , 69, 728-733	10.2	78
136	Optimising TNM Staging of Patients with Prostate Cancer Using WB-MRI. <i>Journal of the Belgian Society of Radiology</i> , 2016 , 100, 101		4
135	Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial. <i>International Journal of Urology</i> , 2016 , 23, 395-403	2.3	15
134	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 133-43	7	19
133	Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. <i>European Urology</i> , 2015 , 68, 787-94	10.2	24

132	Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. <i>European Urology</i> , 2015 , 67, 904-12	10.2	14
131	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 509-21	21.7	138
130	wbMRI to detect bone metastases: critical review on diagnostic accuracy and comparison to other imaging modalities. <i>Clinical and Translational Imaging</i> , 2015 , 3, 141-157	2	10
129	Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. <i>Radiology</i> , 2015 , 275, 155-66	20.5	60
128	Multiplex pyrosequencing assay using AdvISER-MH-PYRO algorithm: a case for rapid and cost-effective genotyping analysis of prostate cancer risk-associated SNPs. <i>BMC Medical Genetics</i> , 2015 , 16, 42	2.1	4
127	What is the Need for Prostatic Biomarkers in Prostate Cancer Management?. <i>Current Urology Reports</i> , 2015 , 16, 70	2.9	9
126	Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. <i>European Urology</i> , 2015 , 67, 157-164	10.2	133
125	Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. <i>European Urology</i> , 2015 , 67, 319-25	10.2	11
124	Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. <i>European Urology</i> , 2015 , 67, 839-49	10.2	63
123	Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. <i>European Urology</i> , 2015 , 67, 470-9	10.2	181
122	Adverse effects of androgen deprivation therapy and strategies to mitigate them. <i>European Urology</i> , 2015 , 67, 825-36	10.2	394
121	Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?. <i>BJU International</i> , 2014 , 113, 189-99	5.6	10
120	One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?. <i>Prostate</i> , 2014 , 74, 469-77	4.2	66
119	Re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. <i>Eur Urol</i> 2013;64:722-30. <i>European Urology</i> , 2014 , 65, e56	10.2	
118	Will new AR inhibitors reshape the prostate cancer landscape?. <i>Lancet Oncology, The</i> , 2014 , 15, 912-3	21.7	
117	Prevention and early detection of prostate cancer. <i>Lancet Oncology, The</i> , 2014 , 15, e484-92	21.7	277
116	Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?. <i>Prostate</i> , 2014 , 74, 365-71	4.2	11
115	Enzalutamide in metastatic prostate cancer before chemotherapy. <i>New England Journal of Medicine</i> , 2014 , 371, 424-33	59.2	1892

114	Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2014 , 15, 592-600	21.7	59
113	Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. <i>European Urology</i> , 2014 , 66, 1101-8	10.2	71
112	Words of wisdom: Re: Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. <i>European Urology</i> , 2014 , 65, 1013-4	10.2	
111	Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. <i>Urology</i> , 2014 , 83, 1122-8	1.6	41
110	Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014 , 50, 1617-27	7.5	120
109	Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. <i>European Urology</i> , 2014 , 66, 479-86	10.2	94
108	Diagnosis and Management of Metastatic Prostate Cancer 2014 , 245-264		
107	Enzalutamide in metastatic prostate cancer before chemotherapy. <i>New England Journal of Medicine</i> , 2014 , 371, 1755-6	59.2	116
106	Patient preferences for treatments to delay bone metastases. <i>Prostate</i> , 2014 , 74, 1488-97	4.2	16
105	Castrate-resistant prostate cancer with peritoneal metastases treated with docetaxel-based chemotherapy. <i>Urologia Internationalis</i> , 2014 , 93, 49-54	1.9	6
104	Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5007-5007	2.2	2
103	Degarelix monotherapy versus luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 86-86	2.2	1
102	The effect of pathologic T-stage and Gleason score on cancer-specific survival for specimen-confined high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 114-114	2.2	
101	Preferences for treatment to delay bone metastases (BM) in patients with castration-resistant prostate cancer (CRPC) at high risk of developing BM.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 117-117	2.2	
100	The effect of pathologic T-stage and Gleason score on cancer-specific survival in patients with positive surgical margins after surgery for high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 140-140	2.2	
99	Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. <i>Annals of Surgical Oncology</i> , 2013 , 20 Suppl 3, S650-60	3.1	101
98	Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 87, 960-7	4	12
97	Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3800-6	2.2	145

96	Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 281-4	2.8	25
95	New and emerging therapies for bone metastases in genitourinary cancers. <i>European Urology</i> , 2013 , 63, 309-20	10.2	36
94	Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. <i>Journal of Magnetic Resonance Imaging</i> , 2013 , 37, 48-58	5.6	106
93	Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. <i>Lancet Oncology</i> , 2013 , 14, 760-8	21.7	221
92	Clinicians versus nomogram: predicting future technetium-99m bone scan positivity in patients with rising prostate-specific antigen after radical prostatectomy for prostate cancer. <i>Urology</i> , 2013 , 81, 956-61	1.6	39
91	Landmarks in hormonal therapy for prostate cancer. <i>BJU International</i> , 2013 , 111, E12-3	5.6	
90	Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?. <i>Urology</i> , 2013 , 81, 998-1004	1.6	22
89	Treatment patterns and characteristics of European patients with castration-resistant prostate cancer. <i>BMC Urology</i> , 2013 , 13, 58	2.2	31
88	Unmet needs in the prediction and detection of metastases in prostate cancer. <i>Oncologist</i> , 2013 , 18, 549-57	5.7	30
87	Novel imaging techniques reshape the landscape in high-risk prostate cancers. <i>Current Opinion in Urology</i> , 2013 , 23, 323-30	2.8	16
86	Access to information and expectations of treatment decisions for prostate cancer patients--results of a European survey. <i>European Journal of Cancer Care</i> , 2013 , 22, 210-8	2.4	5
85	Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation. <i>ClinicoEconomics and Outcomes Research</i> , 2013 , 5, 257-69	1.7	25
84	Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5001-5001	2.2	8
83	Epidemiology and Prevention of Prostate Cancer 2013 , 3-31		
82	Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5002-5002	2.2	0
81	Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. <i>European Urology</i> , 2012 , 61, 584-92	10.2	94
80	Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?. <i>European Urology</i> , 2012 , 62, 68-75	10.2	212
79	Words of wisdom: Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. <i>European Urology</i> , 2012 , 61, 1265-6	10.2	2

78	Testosterone in prostate cancer: the Bethesda consensus. <i>BJU International</i> , 2012 , 110, 344-52	5.6	13
77	New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. <i>BJU International</i> , 2012 , 109, E16; author reply E16-7	5.6	
76	Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy. <i>World Journal of Urology</i> , 2012 , 30, 105-10	4	14
75	Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2012 , 379, 39-46	40	612
74	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). <i>Lancet, The</i> , 2012 , 380, 2018-27	40	594
73	Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. <i>European Urology</i> , 2012 , 62, 472-87	10.2	129
72	Chemoprevention of Prostate Cancer 2012 , 13-24		
71	Designing the selenium and bladder cancer trial (SELEBLAT), a phase III randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. <i>BMC Urology</i> , 2012 , 12, 8	2.2	16
70	Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion. <i>World Journal of Urology</i> , 2012 , 30, 251-6	4	13
69	Evaluation of DCE-MRI postprocessing techniques to assess metastatic bone marrow in patients with prostate cancer. <i>Clinical Imaging</i> , 2012 , 36, 308-15	2.7	12
68	The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. <i>Advances in Urology</i> , 2012 , 2012, 612707	1.6	8
67	Modern Detection of Prostate Cancer Bone Metastasis: Is the Bone Scan Era Over?. <i>Advances in Urology</i> , 2012 , 2012, 893193	1.6	52
66	Chairperson's introduction: Prostate cancer (PCa) is the most frequently detected cancer in the European Union in men above 50 years of age. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S178	7.5	
65	What is the pathophysiology of a hormone-resistant prostate tumour?. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S179-88	7.5	20
64	A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. <i>Journal of Urology</i> , 2011 , 186, 889-97	2.5	105
63	Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer?. <i>European Journal of Anaesthesiology</i> , 2011 , 28, 830-5	2.3	81
62	Maximizing outcomes in genitourinary cancers across the treatment continuum. <i>BJU International</i> , 2011 , 107 Suppl 2, 1-12	5.6	1
61	Is there a prostate-specific antigen upper limit for radical prostatectomy?. <i>BJU International</i> , 2011 , 108, 1093-100	5.6	18

60	Words of Wisdom. Re: pharmacological prevention of side effects of androgen deprivation therapy, a new challenge?. <i>European Urology</i> , 2011 , 59, 172-3	10.2	
59	Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. <i>European Urology</i> , 2011 , 59, 477-94	10.2	537
58	The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. <i>European Urology</i> , 2011 , 60, 270-8	10.2	39
57	Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. <i>European Urology</i> , 2011 , 60, 1045-54	10.2	119
56	Cardiovascular risk during hormonal treatment in patients with prostate cancer. <i>Cancer Management and Research</i> , 2011 , 3, 49-55	3.6	11
55	Chemoprevention of prostate cancer with nutrients and supplements. <i>Cancer Management and Research</i> , 2011 , 3, 91-100	3.6	15
54	Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access prostate-specific antigen assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 285-8	5.9	13
53	The application of adjuvant autologous intravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial. <i>Journal of Translational Medicine</i> , 2010 , 8, 54	8.5	15
52	Quand est-ce que je propose un blocage androgénique complet?. <i>Progrès En Urologie - FMC</i> , 2010 , 20, F2-F5	0	
51	Educational tool-kit on diet and exercise: survey of prostate cancer patients about to receive androgen deprivation therapy. <i>Urology</i> , 2010 , 76, 1434-9	1.6	22
50	The Prostate Cancer gene 3 assay: indications for use in clinical practice. <i>BJU International</i> , 2010 , 105, 452-5	5.6	19
49	Prostate Cancer Management: What Does the Future Hold?. <i>European Urology Supplements</i> , 2010 , 9, 706-714	0.9	1
48	A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. <i>Radiotherapy and Oncology</i> , 2010 , 97, 474-9	5.3	33
47	Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. <i>BJU International</i> , 2010 , 106, 182-7	5.6	52
46	Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. <i>European Urology</i> , 2010 , 57, 836-42	10.2	101
45	Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. <i>European Urology</i> , 2010 , 58, 1-7; discussion 10-1	10.2	123
44	A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient. <i>Urologia Internationalis</i> , 2009 , 83, 373-8	1.9	19
43	Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. <i>European Urology</i> , 2009 , 55, 321	10.2	1

42	Open to debate. The motion: Hormonal blockade should be limited due to significant adverse effects. <i>European Urology</i> , 2009 , 55, 240-3	10.2	0
41	Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. <i>European Urology</i> , 2009 , 56, 594-605	10.2	123
40	Advances in the Therapy of Prostate Cancer-Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways. <i>European Urology Supplements</i> , 2009 , 8, 747-752	0.9	2
39	Management of advanced prostate cancer: can we improve on androgen deprivation therapy?. <i>BJU International</i> , 2008 , 101, 1497-501	5.6	27
38	Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. <i>European Urology</i> , 2008 , 54, 805-13	10.2	103
37	Words of wisdom. Re: toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. <i>European Urology</i> , 2008 , 54, 1202-3	10.2	
36	Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen-Deprivation Therapy. <i>European Urology Supplements</i> , 2008 , 7, 15-21	0.9	18
35	What is New in Hormone Therapy for Prostate Cancer in 2007?. <i>European Urology Supplements</i> , 2008 , 7, 477-483	0.9	2
34	Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1123-31	1.9	16
33	Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5261-8	2.2	67
32	Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer. <i>BJU International</i> , 2007 , 100 Suppl 1, 1-5	5.6	23
31	Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3281-7	2.2	177
30	Preservation of RNA for functional analysis of separated alleles in yeast: comparison of snap-frozen and RNALater solid tissue storage methods. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007 , 45, 1283-7	5.9	17
29	Treatment Options in Prostate Cancer Once Primary Therapy Fails. <i>European Urology Supplements</i> , 2007 , 6, 344-353	0.9	4
28	Advanced Prostate Cancer: Hormones and Beyond. <i>European Urology Supplements</i> , 2007 , 6, 354-364	0.9	3
27	Optimal Testosterone Control and Eligard® . <i>European Urology Supplements</i> , 2007 , 6, 754-760	0.9	7
26	The Importance of Testosterone Control in Prostate Cancer. <i>European Urology Supplements</i> , 2007 , 6, 834-839	0.9	13
25	Calcium store contents control the expression of TRPC1, TRPC3 and TRPV6 proteins in LNCaP prostate cancer cell line. <i>Cell Calcium</i> , 2006 , 39, 401-15	4	49

24	Hormone Therapy: Improving Therapy Decisions and Monitoring. <i>European Urology Supplements</i> , 2006 , 5, 369-376	0.9	7
23	Over- and Underdiagnosis of Prostate Cancer: The Dangers. <i>European Urology Supplements</i> , 2006 , 5, 511-513	0.9	12
22	Eligard® : Advantages for Optimal Testosterone Control. <i>European Urology Supplements</i> , 2006 , 5, 900-904	0.9	6
21	Severe intraoperative acute compartment syndrome with bullous eruption complicating IV fluid administration. <i>Anesthesia and Analgesia</i> , 2006 , 103, 783-4	3.9	7
20	How Good do Current LHRH Agonists Control Testosterone? Can this be Improved with Eligard® ?. <i>European Urology Supplements</i> , 2005 , 4, 30-36	0.9	26
19	Prospective randomized evaluation of emergency extracorporeal shock wave lithotripsy (ESWL) on the short-time outcome of symptomatic ureteral stones. <i>European Urology</i> , 2005 , 47, 855-9	10.2	49
18	Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. <i>Prostate</i> , 2005 , 65, 178-87	4.2	74
17	Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. <i>Clinical Cancer Research</i> , 2005 , 11, 4724-32	12.9	14
16	Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. <i>Cancer Research</i> , 2005 , 65, 7348-55	10.1	46
15	Characterization and multiparameter analysis of visual adverse events in irifolven single-agent phase I and II trials. <i>Clinical Cancer Research</i> , 2004 , 10, 7566-74	12.9	15
14	Role of store-dependent influx of Ca ²⁺ and efflux of K ⁺ in apoptosis of CHO cells. <i>Cell Calcium</i> , 2004 , 36, 421-30	4	19
13	Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. <i>Prostate</i> , 2003 , 56, 163-70	4.2	26
12	Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy. <i>Urology</i> , 2002 , 59, 256-60	1.6	15
11	Apoptotic pathways in prostate cancer. <i>Advances in Cell Aging and Gerontology</i> , 2001 , 6, 23-54		1
10	Blood-borne RT-PCR assay for prostatic-specific transcripts to identify circulating prostate cells in cancer patients. <i>European Urology</i> , 2001 , 39, 65-71	10.2	7
9	Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. <i>Prostate</i> , 2000 , 43, 303-17	4.2	89
8	Immediate vs. delayed androgen deprivation for prostate cancer. <i>Prostate</i> , 2000 , 10, 19-25	4.2	42
7	Intermittent endocrine treatment. <i>World Journal of Urology</i> , 2000 , 18, 183-9	4	4

6	Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 1999 , 7, 1273-80	3-4	59
5	Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and in vitro cultures from such xenografts. <i>Prostate</i> , 1999 , 39, 67-70	4-2	4
4	Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. <i>Prostate</i> , 1999 , 39, 269-79	4-2	19
3	Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. <i>Clinical Chemistry</i> , 1998 , 44, 472-481	5-5	65
2	Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. <i>Urology</i> , 1996 , 48, 67-70	1-6	63
1	Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. <i>Prostate</i> , 1996 , 29, 30-34	4-2	51